OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Paulus on Accelerating Clinical Development With Real-World Data in HER2+ Breast Cancer

July 11th 2025

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Dr Kremyanskaya on the Mechanism of Action of Divesiran in Polycythemia Vera

July 11th 2025

Marina Kremyanskaya, MD, PhD, details the mechanism of action of divesiran for the treatment of patients with polycythemia vera.

Dr Danilov on Sequencing CAR T-Cell Therapy and Bispecific Antibodies in DLBCL

July 11th 2025

Alexey Danilov, MD, PhD, shares essential factors and unanswered questions regarding treatment sequencing in DLBCL.

Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer

July 11th 2025

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

Dr Saad on the Efficacy and Safety of Radium-223 Plus Enzalutamide in mCRPC

July 11th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses efficacy and safety data from the PEACE study of radium-223 and enzalutamide in mCRPC.

Dr Baggio on Prognostic Patterns of CNS Relapse in LBCL

July 11th 2025

Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.

Dr Tan on the Clinical Relevance of T-DXd in HER2-Low/Ultralow Metastatic Breast Cancer

July 11th 2025

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Dr McArthur on the Efficacy of Pembrolizumab Plus Neoadjuvant Chemo in TNBC

July 11th 2025

Heather McArthur, MD, MPH, FASCO, discusses the efficacy of pembrolizumab/chemo and sequencing the regimen in early triple-negative breast cancer.

Dr Sinicrope on the Efficacy and Safety of mFOLFOX6 Plus Atezolizumab in Stage III dMMR CRC

July 10th 2025

Frank A. Sinicrope, MD, discuses the efficacy and safety of atezolizumab plus mFOLFOX6 in patients with stage III dMMR colon cancer

Dr D'Amato on Efficacy Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

July 10th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Dr Deng on the Effects of MSH6 on PARP Inhibitor Sensitivity in Ovarian Cancer

July 10th 2025

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Dr Ganti on the Importance of Molecular Testing in NSCLC

July 10th 2025

Apar Kishor Ganti, MD, discusses the importance of molecular testing in NSCLC and the profiling capabilities of the Oncomine DX Express Test.

Dr Pan on the Novel Therapy Anito-Cel in Relapsed/Refractory Myeloma

July 10th 2025

Darren Pan, MD, highlights the novelty of anito-cel in relapsed/refractory multiple myeloma, including the difference in safety profile vs cilta-cel.

Dr Puri on Future Research Directions in SCLC

July 9th 2025

Sonam Puri, MD, discusses future research directions and ongoing developments in small cell lung cancer.

Dr Hayne on the Implications of the ANZUP 1301 Trial of Mitomycin Plus BCG in NMIBC

July 9th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses mitomycin in combination with BCG in patients with high-risk non–muscle-invasive bladder cancer.

Dr Chehrazi-Raffle on Tivozanib With/Without Nivolumab in Metastatic RCC

July 9th 2025

Alexander Chehrazi-Raffle, MD, discusses findings from an exploratory analysis of the TiNivo-2 trial of tivozanib with/without nivolumab in metastatic RCC.

Dr Chari on the Evolving Determination of Transplant Eligibility in Multiple Myeloma

July 9th 2025

Ajai Chari, MD, expands on the evolving debate surrounding transplant eligibility determination in newly diagnosed multiple myeloma.

Dr Morgans on the Influence of HRQOL Data on the Use of Darolutamide Plus ADT in mHSPC

July 9th 2025

Alicia Morgans, MD, MPH, discusses how PRO data from the ARANOTE trial could inform the selection of darolutamide plus ADT for patients with mHSPC.

Dr Vogel on the European Commission’s Marketing Authorization of Zanidatamab for HER2+ Biliary Tract Cancer

July 9th 2025

Dr Arora on A Retrospective Analysis of Temporal Trends to Assess MCL Incidence From 2000-2021

July 9th 2025

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.